Medical and Surgical Intensive Care Unit, Saint-Roch Hospital, University of Medicine of Nice, 06000 Nice, France.
Crit Care. 2010;14(5):R166. doi: 10.1186/cc9258. Epub 2010 Sep 14.
The purpose of this research is to provide recommendations for the management of glycemic control in critically ill patients.
Twenty-one experts issued recommendations related to one of the five pre-defined categories (glucose target, hypoglycemia, carbohydrate intake, monitoring of glycemia, algorithms and protocols), that were scored on a scale to obtain a strong or weak agreement. The GRADE (Grade of Recommendation, Assessment, Development and Evaluation) system was used, with a strong recommendation indicating a clear advantage for an intervention and a weak recommendation indicating that the balance between desirable and undesirable effects of an intervention is not clearly defined.
A glucose target of less than 10 mmol/L is strongly suggested, using intravenous insulin following a standard protocol, when spontaneous food intake is not possible. Definition of the severe hypoglycemia threshold of 2.2 mmol/L is recommended, regardless of the clinical signs. A general, unique amount of glucose (enteral/parenteral) to administer for any patient cannot be suggested. Glucose measurements should be performed on arterial rather than venous or capillary samples, using central lab or blood gas analysers rather than point-of-care glucose readers.
Thirty recommendations were obtained with a strong (21) and a weak (9) agreement. Among them, only 15 were graded with a high level of quality of evidence, underlying the necessity to continue clinical studies in order to improve the risk-to-benefit ratio of glucose control.
本研究旨在为危重症患者的血糖控制管理提供建议。
21 名专家就五个预先定义的类别之一(血糖目标、低血糖、碳水化合物摄入、血糖监测、算法和方案)提出建议,这些建议按评分进行评分,以获得强烈或弱的一致意见。使用 GRADE(推荐分级评估、制定与评价)系统,强烈推荐表示干预有明显优势,弱推荐表示干预的理想效果和不良效果之间的平衡不明确。
当不能自主进食时,建议使用静脉内胰岛素遵循标准方案,将血糖目标值控制在 10mmol/L 以下。建议将严重低血糖的阈值定义为 2.2mmol/L,无论临床症状如何。不能建议对任何患者都给予相同的葡萄糖(肠内/肠外)量。应使用中心实验室或血气分析仪进行动脉而不是静脉或毛细血管样本的葡萄糖测量,而不是使用即时血糖仪。
得到了 21 项强烈一致和 9 项弱一致的建议。其中,只有 15 项被评为高质量证据水平,这表明有必要继续进行临床研究,以提高血糖控制的风险效益比。